Phase 2 trial of Oxford COVID-19 vaccine in healthy older adults finds it is safe and provokes immune response

The UK's vaccine against SARS-CoV-2 shows similar safety and immunogenicity results in healthy older adults (aged 56 years and over) to those seen in adults aged 18-55 years. The promising early stage results are published in The Lancet. The phase 2 trial finds that the vaccine causes few side effects, and induces immune responses in both parts of the immune system in all age groups and at low and standard dose -
Source: World Pharma News - Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news